INEAS对Vemurafenib的成本效益分析:在突尼斯为基于价值的定价铺平了道路
Mouna Jameleddine1, Nabil Harzallah1, Hela Grati1
1The National Authority for Assessment and Accreditation in Healthcare (INEAS), Tunis 1002, Tunisia; n.harzallah@ineas.tn (N.H.).
Journal of market access & health policy
|October 28, 2024
概括
韦穆拉费尼布在BRAF V600突变黑色素瘤中提供了适度的生存益处,但在突尼斯没有成本效益. 需要大幅降低价格以价值为基础的定价和改善可访问性.
科学领域:
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
- 药物经济学 药物经济学
背景情况:
- 突尼斯的卫生技术评估 (HTA) 机构INEAS对BRAF V600突变黑色素瘤进行了评估.
- 该分析旨在为基于价值的定价和价格谈判策略提供信息.
- 这项研究是由监管机构和突尼斯强制保险计划 (CNAM) 委托进行的.
研究的目的:
- 进行维穆拉费尼布与标准护理的成本效益分析 (CEA).
- 从公共支付者的角度评估维穆拉费尼布的经济价值.
- 为价格谈判和医疗保健资源分配决定提供信息.
主要方法:
- 使用了一个概率马尔科夫队列模型.
- 计算的费用和质量调整的寿命年 (QALYs) 对于vemurafenib和标准护理.
- 分析采用了主要公共付款人 (CNAM) 和公共卫生设施的视角.
主要成果:
- 韦穆拉菲尼布导致平均寿命增加0.38年.
- 增量成本大约为101,106.62.62美元.
- 增量成本效益比 (ICER) 从163,311.40美元/QALY到163,911.46美元/QALY.不等.
结论:
- 根据突尼斯的典型支付意愿 (WTP),Vemurafenib不被认为是具有成本效益的.
- 要实现可接受的ICER,需要大幅降价.
- 调查结果强调需要调整价格,以使药品价值与医疗保健系统能力保持一致.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...